Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen WEZLANA / WEZENLA (ustekinumab-auub by Year

Name: Amgen WEZLANA / WEZENLA (ustekinumab-auub by Year (AMGN)
Creator: Amgen

WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M) ($M)

Quarterly Annual

Amgen WEZLANA / WEZENLA (ustekinumab-auub: $273M in FY2025, up 911.1% from a year earlier.

Latest, FY2025

273

Period ended Dec 31, 2025

Change on a year earlier

+911.1%

27 in FY2024

History

2 years

Since FY2024

Sources

Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03)

Where the FY2025 figure comes from

“|| WEZLANA ® /WEZENLA ™ | 123 | 150 | 273 | 27 | *”

Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	273	+911.1%	Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
FY2024	Dec 31, 2024	27	–	Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Breakdown

What makes up WEZLANA / WEZENLA (ustekinumab-auub

WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Rest of World (ROW) product sales ($M)150 · FY2025

Cite this data

StockData. (2026). Amgen WEZLANA / WEZENLA (ustekinumab-auub ($M), annual FY2024–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-wezlana-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.